Deciphering the Diagnostic Potential of α-Methylacyl CoA Racemase (AMACR) in Prostatic Neoplasms: Alpha-Methylacyl CoA Racemase in Prostatic Cancer

Huma Abbasi; Ikram Udin  Ujjan; Marvi Shaikh; Sandhiya Kumari; Hadiya Sibghatullah; Maleeha Memon

doi:10.54393/pjhs.v6i4.2211

Authors

Huma Abbasi The University of Modern Sciences, Indus Medical College, Tando Mohammad Khan, Pakistan
Ikram Udin Ujjan Liaquat University of Health Sciences, Jamshoro, Pakistan
Marvi Shaikh The University of Modern Sciences, Indus Medical College, Tando Muhammad Khan, PakistanT
Sandhiya Kumari The University of Modern Sciences, Indus Medical College, Tando Muhammad Khan, Pakistan
Hadiya Sibghatullah Department of Pathology, Liaquat University of Medical and Health Sciences, Jamshoro, Pakistan
Maleeha Memon The University of Modern Sciences, Indus Medical College, Tando Muhammad Khan, Pakistan

DOI:

https://doi.org/10.54393/pjhs.v6i4.2211

Keywords:

Prostate Cancer, α-Methylacyl CoA Racemase Expression, Immunohistochemistry, Histological Grading

Abstract

Prostate cancer is a prevalent malignancy that affects males globally, posing a substantial impact both locally and globally. A critical marker for improving prostatic cancer diagnostic accuracy is α-Methylacyl CoA Racemase (AMACR), an enzyme involved in the metabolism of certain fatty acids and bile acid precursors. Objective: To explore the immunohistochemical expression of α-Methylacyl CoA Racemase and assess its association with the histological grading of prostatic adenocarcinoma. Methods: This retrospective cross-sectional study was carried out at Liaquat University of Medical and Health Sciences, Jamshoro between April 2023 to February 2024. Total 71 prostate cancer patients with age range of 45 to 99 years were selected for this study according to the selection criteria. The study used formalin-fixed paraffin-embedded tissue blocks for histopathology to evaluate AMACR expression through immunohistochemistry and the data was analyzed by using the Statistical Package for the Social Sciences (SPSS) for windows. Results: The immunohistochemical study revealed that 57.7% of cases showed AMACR expression, with a significant correlation between the expression levels and the tumor's histological grade (P-value < 0.05). Conclusion: The findings of this study highlighted AMACR's potential as a diagnostic biomarker for aggressive prostate cancer.

References

Badar F and Mahmood S. Cancer in Lahore, Pakistan, 2010-2019: an incidence study. British Medical Journal Open. 2023 Oct; 11(8): e047049. doi: 10.1136/bmjopen-2020-047049.

Soerjomataram I and Bray F. Planning for tomorrow: global cancer incidence and the role of prevention 2020-2070. Nature Reviews Clinical Oncology. 2021 Oct; 18(10): 663-72. doi: 10.1038/s41571-021-00514-z.

Moradi A, Zamani M, Moudi E. A systematic review and meta-analysis on incidence of prostate cancer in Iran. Health Promotion Perspectives. 2019 May; 9(2): 92. doi: 10.15171/hpp.2019.13.

Esfahani M, Ataei N, Panjehpour M. Biomarkers for evaluation of prostate cancer prognosis. Asian Pacific Journal of Cancer Prevention. 2015; 16(7): 2601-11. doi: 10.7314/APJCP.2015.16.7.2601.

Hasan IA, Gaidan HA, Al-Kaabi MM. Diagnostic value of cytokeratin 34 beta E12 (Ck34βE12) and α-Methylacyl-CoA racemase (AMACR) immunohistochemical expression in prostatic lesions. Iranian Journal of Pathology. 2020 May; 15(3): 232. doi: 10.30699/ijp.2020.113544.2229.

Mohler JL, Antonarakis ES, Armstrong AJ, D'Amico AV, Davis BJ, Dorff T et al. Prostate cancer, version 2.2019, NCCN clinical practice guidelines in oncology. Journal of the National Comprehensive Cancer Network. 2019 May; 17(5): 479-505. doi: 10.6004/jnccn.2019.0023.

Luo J, Zha S, Gage WR, Dunn TA, Hicks JL, Bennett CJ et al. α-Methylacyl-CoA racemase: a new molecular marker for prostate cancer. Cancer Research. 2002 Apr; 62(8): 2220-6.

Fu P, Bu C, Cui B, Li N, Wu J. Screening of differentially expressed genes and identification of AMACR as a prognostic marker in prostate cancer. Andrologia. 2021 Jul; 53(6): e14067. doi: 10.1111/and.14067.

Etheridge T, Straus J, Ritter MA, Jarrard DF, Huang W. Semen AMACR protein as a novel method for detecting prostate cancer. InUrologic Oncology: Seminars and Original Investigations 2018 Dec; 36(12): 532-e1. doi: 10.1016/j.urolonc.2018.09.010.

Jiang N, Zhu S, Chen J, Niu Y, Zhou L. A-methylacyl-CoA racemase (AMACR) and prostate-cancer risk: a meta-analysis of 4,385 participants. PLOS One. 2013 Oct; 8(10): e74386. doi: 10.1371/journal.pone.0074386.

Kumar S, Bukhari U, Sikandar B, George A, Memon Y, Khan N et al. Sensitivity of Alpha-Methylacyl-COA Racemase (AMACR) Staining in Prostatic Adenocarcinoma. Journal of Liaquat University of Medical & Health Sciences. 2020 Oct; 19(4).

Virgo KS, Rumble RB, Talcott J. Initial management of noncastrate advanced, recurrent, or metastatic prostate cancer: ASCO guideline update. Journal of Clinical Oncology. 2023 Jul; 41(20): 3652-6. doi: 10.1200/JCO.23.00155.

Boyle HJ, Alibhai S, Decoster L, Efstathiou E, Fizazi K, Mottet N et al. Updated recommendations of the International Society of Geriatric Oncology on prostate cancer management in older patients. European Journal of Cancer. 2019 Jul; 116: 116-36. doi: 10.1016/j.ejca.2019.04.031.

Bratt O, Drevin L, Akre O, Garmo H, Stattin P. Family history and probability of prostate cancer, differentiated by risk category: a nationwide population-based study. Journal of the National Cancer Institute. 2016 Oct; 108(10): djw110. doi: 10.1093/jnci/djw110.

Sreekumar A, Laxman B, Rhodes DR, Bhagavathula S, Harwood J, Giacherio D et al. Humoral immune response to α-methylacyl-CoA racemase and prostate cancer. Journal of the National Cancer Institute. 2004 Jun; 96(11): 834-43. doi: 10.1093/jnci/djh145.

Aldaoud N, Graboski-Bauer A, Abdo N, Al Bashir S, Oweis AO, Ebwaini H et al. ERG expression in prostate cancer biopsies with and without high-grade prostatic intraepithelial neoplasia: a study in Jordanian Arab patients. Research and Reports in Urology. 2019 May: 149-55. doi: 10.2147/RRU.S207843.

Tindall EA, Monare LR, Petersen DC, Van Zyl S, Hardie RA, Segone AM et al. Clinical presentation of prostate cancer in black South Africans. The Prostate. 2014 Jun; 74(8): 880-91. doi: 10.1002/pros.22806.

Yee CH. An Investigation of Lower Urinary Tract Symptoms as the Outcome of Factors beyond Just an Enlarged Prostate (Doctoral dissertation, The Chinese University of Hong Kong (Hong Kong)).

Khan SA. Prostate Cancer in Patients Presenting With Lower Urinary Tract Symptoms. Journal of Surgery Pakistan. 2019 Oct; 24(3): 148-52.

Bangash SA. Expression of Alpha Methyl Acyl-CoaRacemase (AMACR) Immunohistochemistry in Carcinoma Prostate in Tertiary Care Hospital. 2022 Jan; 16(1): 1413. doi: 10.53350/pjmhs221611413.

Magi-Galluzzi C, Luo J, Isaacs WB, Hicks JL, De Marzo AM, Epstein JI. α-Methylacyl-CoA racemase: a variably sensitive immunohistochemical marker for the diagnosis of small prostate cancer foci on needle biopsy. The American Journal of Surgical Pathology. 2003 Aug; 27(8): 1128-33. doi: 10.1097/00000478-200308000-00010.

Akhtar S, Hassan F, Ahmad S, El-Affendi MA, Khan MI. The prevalence of prostate cancer in Pakistan: A systematic review and meta-analysis. Heliyon. 2023 Oct; 9(10). doi: 10.1016/j.heliyon.2023.e20350.

Nomani BH, Alamgir M, Wasti H, Nadeem S. Immunohistochemical expression of Alpha-Methylaceyl-CoA Racemase in Benign Prostate Hyperplasia and Adenocarcinoma Prostate. Isra Medical Journal. 2021 Jan; 13: 15-9.